Search Results

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight loss with a cleaner tolerability profile.

Inhalon Biopharma announced that it has been awarded a $5.7 million contract by the U.S Army Medical Research and Development Command to support a U.S. Army Military Performance Advancement Initiative project to develop new treatments for COVID-19 and other SARS infections.

SAB Biotherapeutics, Inc. today announced that the Navy Medical Research Command (NMRC) is moving forward with a safety and tolerability study to evaluate SAB-176.

Synchron, the endovascular brain-computer interface company developing technology to restore functionality in patients with severe paralysis, announced completion of patient enrollment in the US-based COMMAND trial.

Utah Medical Products, Inc. announces that its Board of Directors approved a quarterly cash dividend of thirty cents per share of common stock payable on April 3, 2024 to stockholders of record at the close of business on March 15, 2024.

Surmodics, Inc. announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems.

Product Creation Studio, a premier provider of engineering and design services, is excited to announce a new partnership with PatchClamp Medtech Inc.